Fobi AI - CEO, Rob Anson.
CEO, Rob Anson.
Source: Fobi AI.
  • Fobi AI (FOBI) has entered into an agreement with Empower Clinics (CBDT) to integrate its Wallet pass platform Passcreator into Empower’s Kai Care COVID-19 testing platform
  • Kai Care customers will have the ability to download a Kai Care Wallet pass directly into the native wallet that lives in all Apple & Android mobile phones
  • The Kai Care Wallet pass can also be used by Empower as a new customer engagement channel
  • Fobi will receive revenue for each wallet pass downloaded and Fobi and Empower will split the proceeds of any new advertising or data monetization revenue
  • A recent report shows the COVID-19 Antigen Testing Market size will reach US$8.3 billion by 2027
  • Empower is an integrated healthcare company that serves patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories
  • Fobi is a cutting-edge data intelligence company that helps clients turn real-time data into actionable insights and personalized customer engagement to generate increased profits
  • Empower Clinics Inc. (CBDT) opened trading at C$0.425 per share
  • Fobi AI Stock (FOBI) opened trading at C$3.02 per share

Fobi AI’s (FOBI) Wallet pass platform Passcreator will be integrated into Empower’s Kai Care COVID-19 testing platform.

The integration of Fobi’s Wallet pass platform into the Kai Care COVID-19 testing platform and back-end lab management system will create a much more secure and seamless customer experience for not only COVID-19 testing but for all other future testing applications as well.  

Kai Care customers will have the ability to download a Kai Care Wallet pass directly into the native wallet that lives in all Apple & Android mobile phones. The Kai Care Pass will then be used for delivering test results directly to the mobile wallet in a safe and secure format.

The new digital offering is very well-timed given various international government mandates in regards to digital health passport requirements with proof of vaccinations and negative Covid test requirements.

The Kai Care Wallet pass can also be used by Empower as a new customer engagement channel.  Campaigns for additional Kai Labs tests or relevant 3rd party products or services can be pushed out to their customers through banner ads on the front of the wallet pass, links on the back of the wallet pass, or through push notifications to customer mobile phone lock screens.  The new integrated solution also has a very high level of data security, with Fobi’s Wallet pass powered by Hedera Hashgraph.

This new engagement channel also opens up potentially new advertising and data monetization options for both Empower and Fobi. In particular, Empower can now use the wallet pass to promote and monetize products such as their own new testing products, as well as other 3rd party products such as travel insurance, etc.  

Under the terms of the agreement, Fobi will receive revenue for each wallet pass downloaded and Fobi and Empower will split the proceeds of any new advertising or data monetization revenue opportunities realized from this service agreement.

Empower CEO Steven McAuley commented on the partnership with Fobi.

“Testing and vaccinations are becoming a pillar of everyday life as society continues its fight against COVID-19. I’m proud to deepen our relationship with Fobi and meet the massive demand for reliable, secure and easy COVID-19 testing results and verification sharing. By working together our companies are supporting a safe reopening for individuals, businesses, schools, and so much more.”

A recent report from Grandview Research shows the COVID-19 Antigen Testing Market size will reach US$8.3 billion by 2027.  With Fobi’s Wallet pass platform enabling an even more secure and seamless customer experience for Covid testing and result verification, it is anticipated that Empower will increase its share of that market significantly.

Fobi CEO Rob Anson commented,

“Powering the Kai Care Wallet pass and supporting Empower to leverage our artificial intelligence data applications clearly provides Empower Clinics and Kai Care with a clear product differentiator in the testing marketplace. There are other testing providers out there, but none of which offer real time results delivered directly to the wallet. The Kai Care Wallet pass solution will provide the means to deliver a new level of personalized client engagement, scheduling and messaging. This new product release also provides Empower and Fobi with the ability to generate additional revenue through the data and advertising monetization opportunities. We are very excited to continue our support of our strong partnership with Empower Clinics.”

Empower is an integrated healthcare company that serves patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories.

Fobi is a cutting-edge data intelligence company that helps clients turn real-time data into actionable insights and personalized customer engagement to generate increased profits.

Empower Clinics Inc. (CBDT) opened trading at C$0.425 per share.

More From The Market Online

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.